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aBStraCt
Introduction: Bleeding is currently the most 
common non-cardiac complication of therapy 
in patients with acute coronary syndromes 
(ACS), and may itself be associated with 
adverse outcomes. The aim of this study was 
to determine the effect of hemoglobin drop 
during hospital stay on outcome among 
patients with ACS.
Methods: Using Cox proportional-hazards 
modeling, we examined the association 
between hemoglobin drop and death or 
myocardial infarction (MI) at 6 months in 
1172 patients admitted with ACS to an 
intensive cardiac care unit. Patients 
were	stratified	according	to	quartiles	of	
hemoglobin drop: Q1, ≤0.8 g/dL; Q2, 0.9-
1.5 g/dL; Q3, 1.6-2.3 g/dL; Q4, ≥2.4 g/dL. 
We	also	identified	independent	predictors	of	
increased hemoglobin drop (≥2.4 g/dL) using 
multivariate logistic regression analysis.
Results: Median nadir hemoglobin 
concentration was 1.5 g/dL lower (IQR 0.8-
2.3) compared with baseline hemoglobin 
(p<0.0001). Independent predictors of 
increased hemoglobin drop included older 
age, renal dysfunction, lower weight, and use 
of thrombolytic therapy, glycoprotein IIb/IIIa 
inhibitors, nitrates, and percutaneous coronary 
intervention. Higher levels of hemoglobin 
drop were associated with increased rates of 
6-month mortality (8.0% vs. 9.4% vs. 9.6% vs. 
15.7%; p for trend=0.014) and 6-month death/
MI (12.4% vs. 17.0% vs. 17.2% vs. 22.1%; p 
for trend=0.021). Using Q1 as reference group, 
the adjusted hazard ratio (HR) for 6-month 
reSuMo
Impacto prognóstico da redução intra- 
-hospitalar da concentração de hemoglo-
bina em doentes com síndrome coronária 
aguda
Introdução: As hemorragias são actualmente 
a complicação terapêutica não-cardíaca mais 
comum em doentes com síndrome coronária 
aguda (SCA) e podem estar associadas a 
eventos adversos. O objectivo deste estudo foi 
determinar o efeito da queda da concentração 
de hemoglobina durante o internamento 
hospitalar no prognóstico de doentes com SCA.
Métodos: Foi utilizado o modelo de riscos 
proporcionais de Cox para estudar a 
associação entre a queda de hemoglobina e a 
ocorrência de morte ou enfarte do miocárdio 
aos 6 meses em 1172 doentes admitidos 
na nossa Unidade de Cuidados Intensivos 
Cardíacos com SCA. Os doentes foram 
estratificados	de	acordo	com	o	quartil	de	
queda de hemoglobina (quartil 1: ≤0,8 g/
dL; quartil 2: 0,9-1,5 g/dL; quartil 3: 1,6-
2,3 g/dL; quartil 4: ≥2,4 g/dL). Foram ainda 
identificados	os	preditores	de	uma	queda	
elevada da concentração de hemoglobina 
(≥2,4 g/dL) utilizando um modelo de regressão 
logística multivariada.
Resultados: A hemoglobina mínima mediana 
foi 1,5 g/dL inferior (IQR 0,8-2,3 g/dL) 
relativamente à hemoglobina da admissão 
(p<0.0001). Os preditores independentes 
de uma queda elevada da concentração de 
hemoglobina incluíram idade avançada, 
disfunção renal, baixo peso, administração 
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cardiovascular risk associated with bleeding(7-9). 
The Fifth Organization to Assess Strategies in 
Ischemic Syndromes (OASIS-5) trial showed 
that the reduction in bleeding at 9 days with 
fondaparinux was associated with lower long-
term mortality and morbidity in patients with 
non-ST-segment elevation ACS(10).
Several	 definitions	 of	 bleeding	 have	 been	
used in clinical trials and registries, leading 
to disparities in the reported incidence of 
bleeding events within the same population(11). 
Bleeding assessed with clinical criteria (such as 
the Global Use of Strategies to Open Occluded 
Coronary Arteries [GUSTO] bleeding scale)(12) 
appears to be more important than that assessed 
by laboratory criteria (such as the Thrombolysis 
In	Myocardial	Infarction	[TIMI]	classification)(13) 
INtroduCtIoN
Contemporary treatment of acute coronary syndromes (ACS) includes the combined 
use of anticoagulants and antiplatelet agents, 
coupled with early use of cardiac catheterization 
and revascularization in high-risk patients(1,2). 
Although this approach has improved the rate 
of recurrent ischemic coronary events, it has 
also increased the potential for bleeding com-
plications. Bleeding has itself been associated 
with a higher risk of ischemic events and death 
in observational analyses(3-5), although it has been 
suggested that bleeding may often be merely a 
marker for patients at higher risk for adverse 
outcomes(6). There are also data suggesting that 
blood transfusion may contribute to the increased 
mortality and 6-month death/MI among 
patients in the highest quartile of hemoglobin 
drop	was	1.83	(95%	confidence	interval	[CI]	
1.08-3.11; p=0.026) and 1.60 (95% CI 1.04-
2.44; p=0.031) respectively. Considered 
as a continuous variable, the adjusted HR 
for 6-month mortality was 1.16 (95% CI 
1.01-1.32; p=0.030) per 1 g/dL increase in 
hemoglobin drop.
Conclusions: A decrease in hemoglobin 
frequently occurs during hospitalization for 
ACS and is independently associated with 
adverse outcomes.
Key words 
Acute coronary syndrome; Myocardial infarction; Bleeding; 
Hemoglobin; Anemia; Prognosis; Blood transfusion.
de	terapêutica	fibrinolítica,	inibidores	da	
glicoproteína IIb/IIIa, nitratos, e a realização 
de intervenção coronária percutânea. 
Os doentes com níveis mais elevados de 
queda de hemoglobina apresentaram maior 
mortalidade aos 6 meses (8,0% versus 9,4% 
versus 9,6% versus 15,7%; p=0,014) e maior 
incidência de morte ou enfarte do miocárdio 
aos 6 meses (12,4% versus 17,0% versus 
17,2% versus 22,1%; p=0,021). Utilizando 
o quartil 1 como referência, o hazard ratio 
(HR) ajustado para mortalidade aos 6 meses 
e ocorrência de morte/enfarte do miocárdio 
aos 6 meses para os doentes no quartil mais 
elevado de queda de hemoglobina foi 1,83 
(intervalo	de	confiança	[IC]	95%	1,08-3,11;	
p=0,026) e 1,60 (IC 95% 1,04-2,44; p=0,031), 
respectivamente. Introduzida no modelo como 
variável contínua, o HR ajustado de morte 
aos 6 meses para cada aumento de 1 g/dL na 
queda de hemoglobina foi 1,16 (IC 95% 1,01-
1,32; p=0,030).
Conclusões: Durante o internamento por SCA 
é frequente uma queda na concentração de 
hemoglobina, a qual está associada de forma 
independente a um risco mais elevado de 
eventos adversos aos 6 meses.
 
Palavras-Chave 
Síndrome coronária aguda; Enfarte do miocárdio; 
Hemorragia; Hemoglobina; Anemia; Prognóstico; Transfusão
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the patient remained in the ICCU. Hemoglobin 
concentration was also determined before and 
8 h after percutaneous coronary intervention as 
routine procedure in our center. After discharge 
from the ICCU, hemoglobin concentrations 
were obtained according to the discretion of 
the treating physician. In the present study, 
we analyzed admission hemoglobin and nadir 
hemoglobin (the lowest hemoglobin value during 
hospital stay). Discharge hemoglobin (the last 
hemoglobin level obtained during hospital 
stay) was also analyzed among survivors of hos-
pitalization. Hemoglobin drop during hospital 
course	 was	 defined	 as	 the	 difference	 between	
admission hemoglobin and nadir hemoglobin 
(g/dL). Patients in whom the initial value was 
the lowest were assigned a “drop” of 0 (n=110). 
Data on blood transfusions were collected. 
Bleeding	complications	were	defined	according	
to TIMI criteria(13).	Major	bleeding	was	defined	
as intracranial hemorrhage or a ≥5 g/dL decrease 
in hemoglobin concentration; minor bleeding 
was	defined	as	a	≥3 g/dL decrease in hemoglobin 
concentration if blood loss was observed, and as 
a ≥4 g/dL decrease in hemoglobin concentration 
if not. Data on bleeding and hemoglobin 
decline occurring after coronary artery bypass 
graft (CABG) surgery were not included in our 
analyses (this intervention was performed in 
referral centers). 
Follow-up and outcomes
The primary end point was six-month 
all-cause mortality. Secondary end points 
were occurrence of the composite of death 
or myocardial infarction (MI). Patients were 
monitored for at least six months or until the 
primary endpoint was reached. Follow-up was 
by telephone, and by review of the databases 
and medical records of the hospital. Mortality 
follow-up was complete for 1145 patients (98% 
of the study sample) at six months.
Statistical analysis
Patients were grouped according to quartiles 
of hemoglobin drop during hospital stay. The 
baseline characteristics of the groups were 
compared using chi-square tests for categorical 
variables and analysis of variance for continuous 
variables. A test for trend across ordered groups 
was performed for the four groups of hemoglobin 
drop.
in terms of predicting clinical outcomes in 
patients with ACS(14). Nevertheless, limited data 
exist regarding the effect of hemoglobin con-
centration changes on outcome among patients 
with ACS(15). The aim of the present study was to 
determine the predictors and prognostic impact 
of hemoglobin drop during hospitalization among 
patients with ACS in a real-world setting.
MetHodS
Patients
For this analysis, we included 1172 patients 
admitted to our six-bed intensive cardiac care 
unit (ICCU) with ACS between January 2004 
and March 2007. Patients considered in the 
present study had a history of chest pain at rest 
or other symptoms suggestive of an ACS, with 
the most recent episode occurring within 24 
hours of admission. This could be associated 
with either transient or persistent ST-segment 
elevation, ST-segment depression, or T-wave 
inversion on the electrocardiogram, or elevated 
levels of biomarkers of myocardial damage. The 
biomarkers used were cardiac troponin I (cTnI) 
and creatine kinase MB mass assay (CK-MB), 
with a threshold for positivity of 0.06 and 3.5 ng/
mL respectively. Patients included had at least 
two determinations of hemoglobin concentration 
(the	first	 on	admission)	 separated	by	24	hours.	
Patients with unstable angina and a normal ECG 
on admission (n=17) were also included. Left 
ventricular ejection fraction (LVEF) was assessed 
by echocardiography within 2 to 6 days of 
admission.	Glomerular	filtration	rate	(GFR)	was	
estimated	using	the	four-component	Modification	
of Diet in Renal Disease (MDRD) equation(16): 
Estimated GFR (ml per minute per 1.73 m2 of 
body surface area) = 186 x (serum creatinine 
[mg/dL])-1.154 x (age [in years])-0.203. For women, 
the value was multiplied by 0.742. Although this 
was a retrospective study, clinical data regarding 
demographic and presentation characteristics, 
medical history, and in-hospital medication and 
procedures were collected prospectively and 
recorded on a computer database of ACS patients 
admitted to our institution’s ICCU.
Hemoglobin measurements
Hemoglobin concentration was determined 
on admission and every 24 h thereafter while 
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across the ordered groups. All p values were 
two-sided, and a p value of less than 0.05 was 
considered	 to	 indicate	 statistical	 significance.	
Statistical analyses were performed using SPSS 
version 13.0 (SPSS Inc., Chicago, Illinois, 
USA).
reSultS
Baseline characteristics
Between January 2004 and March 2007, 
1228 patients were admitted to the ICCU of 
our institution with the diagnosis of ACS. We 
excluded 56 patients due to missing repeated 
hemoglobin measurements (21 of these 
patients died within 24 hours after admission, 
8	 patients	 were	 transferred	 in	 the	 first	 24	
hours to referral centers for emergency cardiac 
surgery for mechanical complications [n=4] 
or rescue percutaneous coronary intervention 
[n=4], and 27 patients had a single hemoglobin 
determination	 on	 admission).	 The	 final	 study	
population consisted of the remaining 1172 
patients (592 had ST-segment elevation MI, 542 
had non-ST-segment elevation MI, and 38 had 
unstable angina).  
Forty-seven patients died during hospital-
ization, and 74 patients died in the follow-up 
after hospital discharge and before 6 months. 
According to the World Health Organization 
criteria (hemoglobin <13 g/dL in men and 
<12 g/dL in women), anemia was present in 
244 patients on admission (20.8%) and in 
458 survivors at discharge (40.7%). During 
hospitalization, major and minor bleeding (TIMI 
criteria) occurred in 25 (2.1%) and 87 (7.4%) 
patients respectively.
Median nadir hemoglobin concentration 
was 1.5 g/dL lower (IQR 0.8-2.3) than base-
line hemoglobin (p<0.0001). Hemoglobin drop 
during hospital course ranged from 0 to 8.3 g/
dL. The clinical characteristics of patients 
according to quartiles of hemoglobin drop are 
shown in Table I. Patients with higher decline 
of hemoglobin concentration were less likely 
to be females, presented more frequently with 
ST-segment elevation, more often had renal 
dysfunction (GFR <60 ml/min/1.73 m2), and 
had higher blood pressure and heart rate on 
admission. Although patients with higher 
hemoglobin drop during hospital course had 
Multivariate logistic regression analysis was 
performed to determine independent predictors 
of increased hemoglobin drop during hospital 
course. Variables included in the analysis were 
age, gender and weight; history of diabetes 
mellitus, MI, hypertension, or coronary artery 
revascularization; smoking status, GFR, base-
line hemoglobin, and Killip class at admission; 
use of heparin, glycoprotein IIb/IIIa inhibitors, 
thrombolytic therapy, intravenous inotropic 
agents, nitrates, coronary angiography, percuta-
neous coronary revascularization, and intra-
aortic balloon pump insertion.
Cox proportional-hazards modeling was 
performed to test the association between 
hemoglobin drop and adverse events at six-
months. Multivariable-adjusted Cox models 
were constructed by forcing hemoglobin drop 
or nadir hemoglobin as either continuous 
or categorical variables (quartiles of the 
distribution) into the models and including 
all other covariates associated with six-month 
adverse events. The threshold for retaining a 
variable	 in	 the	 final	 multivariable	 model	 was	
set at p<0.1. The covariates considered in the 
model were age, gender, history of diabetes, 
history of hypertension, history of dyslipidemia, 
smoking status, prior MI, treatment with cardiac 
medications (aspirin, beta-blockers, angiotensin-
converting enzyme [ACE] inhibitors, statins) 
before hospitalization, history of coronary artery 
revascularization, baseline GFR (per 10 ml/min/ 
1.73 m2 decrement), Killip class on admission, 
admission heart rate, systolic and diastolic blood 
pressure at presentation, ST-elevation infarction, 
baseline hemoglobin concentration, thrombolytic 
therapy, percutaneous or surgical coronary 
artery revascularization during hospitalization, 
LVEF	stratified	as	above	or	below	50%,	length	of	
hospital stay, and blood transfusion. Additional 
models were developed excluding patients 
who underwent CABG surgery (n=141), and 
excluding patients who died during the index 
hospitalization (n=47). For each model, the 
proportional hazards assumption was tested and 
found to be appropriate.
Kaplan-Meier analysis was used to illustrate 
6-month event-free survival for patients who 
had different degrees of hemoglobin drop. The 
log-rank test was used to test the equality of the 
survivor function across groups, and the test for 
trend of the survivor function was performed 
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Table I. Baseline clinical characteristics according to quartiles of hemoglobin drop
Characteristic Quartile of hemoglobin drop during hospital course (range, g/dl)
 First (n=318) Second (n=289) third (n=276) Fourth (n=289) p for trend
 (≤0.8) (0.9-1.5) (1.6-2.3) (≥2.4)
demographic     
   Age (years) 64±13 64±13 66±14 65±13 0.43
   Female gender 109 (34.3) 78 (27.0) 79 (28.6) 63 (21.8) 0.008
   Weight (kg) 75.0±13.0 74.2±13.3 74.8±11.6 73.9±12.3 0.72
Medical history     
   Diabetes mellitus 85 (26.7) 81 (28.0) 80 (29.0) 80 (27.7) 0.94
   Hypertension 195 (61.3) 182 (63.0) 191 (69.2) 176 (60.9) 0.15
   Dyslipidemia 145 (45.6) 142 (49.1) 132 (47.8) 133 (46.0) 0.81
   Current smoking  69 (21.7) 73 (25.3) 61 (22.1) 80 (27.7) 0.28
   Prior MI 56 (17.6) 56 (19.4) 52 (18.8) 41 (14.2) 0.36
   Prior PCI 10 (3.1) 15 (5.2) 12 (4.3) 13 (4.5) 0.65
   Prior CABG 14 (4.4) 13 (4.5) 7 (2.5) 6 (2.1) 0.24
Medications at presentation     
   Aspirin 74 (23.3) 83 (28.7) 67 (24.3) 59 (20.4) 0.13
   Beta-blocker 61 (19.2) 69 (23.9) 55 (19.9) 45 (15.6) 0.10
   ACE inhibitor 69 (21.7) 80 (27.7) 79 (28.6) 65 (22.5) 0.12
   Statin 83 (26.1) 91 (31.5) 76 (27.5) 62 (21.5) 0.06
Presentation characteristics     
   ST elevation 127 (39.9) 138 (47.8) 143 (51.8) 184 (63.7) <0.0001
   Killip class >I 60 (18.9) 63 (21.8) 69 (25.0) 74 (25.6) 0.17
   SBP (mmHg) 134±25 136±26 141±27 143±29 <0.0001
   DBP (mmHg) 75±15 76±15 79±16 82±18 <0.0001
   Heart rate (bpm) 74±17 75±19 78±19 80±21 0.002
   Renal dysfunction* 64 (20.1) 46 (16.0) 61 (22.1) 76 (26.3) 0.022
   Hemoglobin (g/dL) 13.1±1.8 13.8±1.6 14.0±1.6 14.7±1.7 <0.0001
   WBC count (103/ul) 9.7±3.0 10.7±3.6 11.1±3.8 12.2±4.5 <0.0001
   Platelet count (103/ul) 209±61 216±66 229±71 229±79 <0.0001
   Blood glucose (mg/dL) 143±76 155±72 165±76 178±94 <0.0001
ACE: angiotensin-converting enzyme; CABG: coronary artery bypass grafting; DBP: diastolic blood pressure; MI: myocardial infarction; PCI: percutaneous coronary intervention; SBP: 
systolic blood pressure; WBC: white blood cell.
*Glomerular	filtration	rate	<60	ml/min/1.73	m2.
Data	are	presented	as	number	(%)	of	patients	(categorical	variables)	or	mean	value	±SD	(continuous	variables).	Glomerular	filtration	rate,	hemoglobin,	WBC	and	platelet	counts,	and	
blood glucose were determined on admission.
Admission hemoglobin*
Nadir hemoglobin*
Discharge hemoglobin*
H
em
o
gl
o
b
in
 (
g/
d
l
)
Quartile of hemoglobin drop
Figure 1. Box-and-whisker plots of changes in hemoglobin concentration during hospital course according to quartile of 
hemoglobin drop. Data labels in each box refer to median values of hemoglobin concentration (g/dL).
*p<0.0001 for trend across ordered groups.
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(Table II). Mean duration of hospital stay was 
significantly	 longer	 for	 patients	 in	 the	 highest	
quartiles of hemoglobin reduction (6.7 vs. 7.3 
vs. 8.5 vs. 9.6 days, p<0.0001 for trend).
Independent predictors of a ≥2.4 g/dL 
reduction in hemoglobin (75th percentile) in a 
multivariate logistic regression model included 
older age, lower GFR, higher admission 
hemoglobin, lower weight, and use of intravenous 
inotropic agents, thrombolytic therapy, 
glycoprotein IIb/IIIa inhibitors, nitrates, and 
percutaneous coronary intervention (Table III).
Clinical outcomes
Figure 2 shows the Kaplan-Meier curves for 
6-month survival by quartiles of hemoglobin 
drop.	 Survival	 decreased	 significantly	 as	
hemoglobin drop severity increased. Higher 
levels of hemoglobin drop were associated with 
increased rates of 6-month mortality (8.0% vs. 
9.4% vs. 9.6% vs. 15.7%; p for trend=0.014) 
and 6-month death/MI (12.4% vs. 17.0% vs. 
17.2% vs. 22.1%; p for trend=0.021). Table IV 
higher hemoglobin concentrations on admission, 
their levels of nadir and discharge hemoglobin 
were lower than in patients in the lowest quartile 
of hemoglobin drop (p<0.0001) (Figure 1). In 
addition, patients with higher hemoglobin drop 
had higher white blood cell and platelet counts, 
and higher blood glucose levels on admission 
(all p<0.0001) (Table I).
The use of thrombolytic agents, unfractionated 
heparin, and percutaneous coronary revascu-
larization procedures was more frequent among 
patients with higher levels of hemoglobin drop 
during hospital stay, with a trend towards 
increased use of glycoprotein IIb/IIIa receptor 
blockers in these patients. Moreover, patients 
with higher hemoglobin decline were also more 
frequently treated with ACE inhibitors, nitrates 
and intravenous vasopressor therapy, and more 
often received blood transfusions. Patients with 
increased hemoglobin drop more often had left 
ventricular systolic dysfunction (LVEF <50%) 
on echocardiography, and were more likely 
to develop heart failure during hospital stay 
Table II. Management, angiographic and echocardiographic features, and outcomes of patients according to quartiles of 
hemoglobin drop
Characteristic Quartile of hemoglobin drop during hospital course (range, g/dl)
 First (n=318) Second (n=289) third (n=276) Fourth (n=289) p for trend
 (≤0.8) (0.9-1.5) (1.6-2.3)  (≥2.4) 
In-hospital medication     
   Aspirin 317 (99.7) 288 (99.7) 275 (99.6) 289 (100) 0.80
   Beta-blocker 278 (87.4) 252 (87.2) 239 (86.6) 255 (88.2) 0.95
   Statin 311 (97.8) 282 (97.6) 273 (98.9) 285 (98.6) 0.57
   ACE inhibitor 277 (87.1) 265 (91.7) 258 (93.5) 269 (93.1) 0.020
   Nitrates 172 (54.1) 192 (66.4) 191 (69.2) 211 (73.0) <0.0001
   Thienopyridine 223 (70.1) 187 (64.7) 180 (65.2) 175 (60.6) 0.10
   UFH 39 (12.3) 59 (20.4) 73 (26.5) 81 (28.2) <0.0001
   LMWH 303 (95.3) 274 (94.8) 256 (93.4) 269 (93.4) 0.68
   GP IIb/IIIa receptor blockers 8 (2.5) 13 (4.5) 13 (4.7) 21 (7.3) 0.053
   Thrombolytic therapy 61 (19.2) 73 (25.3) 83 (30.1) 112 (38.8) <0.0001
   IV inotropic agents 9 (2.8) 16 (5.5) 11 (4.0) 31 (10.7) <0.0001
   Blood transfusion 7 (2.2) 5 (1.7) 7 (2.5) 19 (6.6) 0.003
Procedures     
   Cardiac catheterization 218 (68.6) 202 (69.9) 195 (70.7) 199 (68.9) 0.94
   PCI 77 (24.2) 83 (28.7) 92 (33.3) 111 (38.4) 0.001
   CABG 34 (10.7) 43 (14.9) 33 (12.0) 31 (10.7) 0.36
   Intra-aortic balloon pump 1 (0.3) 1 (0.3) 1 (0.4) 3 (1.0) 0.55
LVSD 169 (54.0) 168 (59.8) 179 (66.1) 210 (73.2) <0.0001
outcomes    
   Killip class II-IV 94 (29.6) 95 (32.9) 97 (35.1) 129 (44.6) 0.001
   In-hospital mortality 6 (1.9) 12 (4.2) 10 (3.6) 19 (6.6) 0.032
   6-month mortality 25 (8.0) 26 (9.4) 26 (9.6) 44 (15.7) 0.014
   6-month death/MI 39 (12.4) 47 (17.0) 47 (17.2) 62 (22.1) 0.021
Data are presented as number (%) of patients (categorical variables) or mean value ±SD (continuous variables). 
ACE: angiotensin-converting enzyme; CABG: coronary artery bypass grafting; GP: glycoprotein; LMWH: low molecular weight heparin; LVSD: left ventricular systolic dysfunction; MI: 
myocardial infarction; PCI: percutaneous coronary intervention; UFH: unfractionated heparin.
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Table III. Independent predictors of increased hemoglobin drop*
Variable ß-coefficient or (95% CI) p 
Age (per 1-year increase) 0.02 1.02 (1.01-1.04) 0.012
GFR (per 10-ml/min/1.73 m2 decrement) 0.08 1.08 (1.02-1.15) 0.008
Weight (per 10-kg increment) -0.16 0.85 (0.75-0.98) 0.021
IV inotropic agents 1.17 3.21 (1.69-6.09) <0.0001
Thrombolytic therapy 0.57 1.77 (1.12-2.81) 0.014
Glycoprotein IIb/IIIa inhibitors 0.85 2.34 (1.18-4.63) 0.015
Nitrates 0.50 1.65 (1.17-2.33) 0.004
PCI 0.59 1.80 (1.23-2.64) 0.002
Admission hemoglobin (per 1-g/dL increment) 0.55 1.74 (1.54-1.96) <0.0001
*Hemoglobin drop ≥2.4 g/dL (75th percentile)
GFR:	glomerular	filtration	rate;	PCI:	percutaneous	coronary	intervention
Log rank p=0.01
Follow-up (days)
Figure 2. Kaplan-Meier curve for overall mortality according to quartile of hemoglobin drop (range, g/dL) during hospital 
course.
Table IV. Hazard ratios for death according to quartiles of hemoglobin drop and nadir hemoglobin during hospital 
course.
 6-month mortality (%) unadjusted Hr (95% CI) adjusted Hr (95% CI)
Quartiles of hemoglobin drop 
(range, g/dl)   
   First (≤0.8) 8.0 1.0‡ 
   Second (0.9-1.5) 9.4 1.23 (0.71-2.15) 1.33 (0.74-2.39)
   Third (1.6-2.3) 9.6 1.25 (0.72-2.18) 1.25 (0.71-2.23)
   Fourth (≥2.4) 15.7* 2.12 (1.29-3.48) 1.83 (1.08-3.11)
Quartiles of nadir hemoglobin 
(range, g/dl)   
   First (≤11.0) 24.4 6.38 (3.45-11.81) 2.33 (1.12-4.84)
   Second (11.1-12.3) 11.5 2.94 (1.52-5.69) 1.77 (0.85-3.71)
   Third (12.4-13.4) 3.1 0.75 (0.32-1.79) 0.62 (0.24-1.57)
   Fourth (≥13.5) 4.1† 1.0‡ 
*p=0.014 for trend; †p<0.0001 for trend; ‡This group served as the reference group
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increased 6-month mortality rates (Figure 4).
Further analyses were performed excluding 
patients who underwent CABG surgery (n=141) 
from the study population. In the selected 
population of patients not undergoing CABG 
surgery, results were similar to those reported 
for the initial patient population. Increased 
hemoglobin drop was associated with higher 
6-month mortality. Compared with patients in the 
lowest quartile of hemoglobin drop, the adjusted 
HR for 6-month mortality among patients in the 
highest quartile of hemoglobin drop was 2.44 
(95% CI 1.37-4.35; p=0.002). For each 1-g/dL 
increase in hemoglobin drop the adjusted HR 
for 6-month mortality was 1.31 (95% CI 1.12-
1.53; p=0.001).
Moreover, results were similar after excluding 
patients who died during the index hospitalization 
(n=47) from the analyses. Higher levels of 
hemoglobin drop during hospital stay were still 
associated with increased mortality at six months 
in patients who survived the hospitalization. For 
each 1-g/dL increase in hemoglobin drop the 
adjusted HR for 6-month mortality was 1.19 
(95% CI 1.00-1.41; p=0.045).
Nadir hemoglobin was strongly associated 
with mortality at six months. A tendency for a 
J-shaped rather than monotonic relationship 
presents the results of unadjusted and adjusted 
Cox regression models for 6-month mortality 
by quartiles of hemoglobin drop and nadir 
hemoglobin. After adjustment for potential 
confounders, patients in the highest quartile of 
hemoglobin decline had worse outcomes than 
patients	 in	 the	 first	 quartile	 (reference	 group).	
The adjusted hazard ratios (HR) for 6-month 
mortality and 6-month death/MI among patients 
in the highest quartile of hemoglobin drop were 
1.83	 (95%	 confidence	 interval	 [CI]	 1.08	 to	
3.11; p=0.026) and 1.60 (95% CI 1.04 to 2.44; 
p=0.031) respectively, compared with patients 
in the lowest quartile of hemoglobin drop.
When considered as a continuous variable 
in 1-g/dL increments, a graded relationship was 
seen between hemoglobin drop and 6-month 
death and death/MI (Figure 3). The adjusted 
HR for each 1-g/dL increase in hemoglobin drop 
was 1.16 (95% CI 1.01 to 1.32; p=0.030) and 
1.12 (95% CI 1.01-1.25; p=0.041) for 6-month 
mortality and 6-month death/MI respectively 
(Table V). Since thrombolytic therapy and 
intravenous inotropes were strong predictors of 
an increased hemoglobin drop, we also analyzed 
our	data	stratified	by	initial	diagnosis.	In	both	ST-
elevation MI and non-ST-elevation ACS, higher 
levels of hemoglobin drop were associated with 
Hemoglobin drop, g/dl
Figure 3. Crude six-month mortality and six-month death/myocardial infarction (MI) according to hemoglobin drop (g/
dL). At the top of each column, the rates of six-month mortality and death/MI (% of patients) are noted. Data labels at 
the bottom of the columns refer to the number of patients in each group of hemoglobin drop.
*p<0.001 for trend.
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for comorbidities, clinical presentation, hos-
pital treatment, and hemoglobin drop, blood 
transfusion was independently associated with 
an increased risk of 6-month mortality (adjusted 
HR 1.94, 95% CI 1.06 to 3.55; p=0.032) and 
6-month death/MI (adjusted HR 1.77, 95% CI 
1.03 to 3.04; p=0.039) (Table V).
dISCuSSIoN
In this single-center observational study, 
we found a graded independent association 
between higher levels of hemoglobin drop 
during hospitalization and increased mortality 
in	 patients	 admitted	 with	 ACS.	 Our	 findings	
provide additional evidence to previous reports 
regarding the impact of bleeding and anemia 
was observed between nadir hemoglobin and 
adjusted mortality. The adjusted HR for 6-month 
mortality for patients in the lowest quartile of 
nadir hemoglobin was 2.33 (95% CI 1.12-4.84; 
p=0.024), compared with patients in the highest 
quartile (Table IV).
Blood transfusion
Thirty-eight patients (3.2%) underwent at 
least one blood transfusion. Mean (±SD) nadir 
hemoglobin value among transfused patients 
was 8.0±0.7 g/dL (range, 6.4 to 9.4) compared 
with 12.4±1.6 g/dL (range, 7.5 to 16.9) among 
nontransfused patients (p<0.0001). Transfused 
patients had a higher absolute rate of death 
(40.5% vs. 9.6%; p<0.0001) and death/MI (48.6% 
vs. 16.0%; p<0.0001) at 6 months compared 
with nontransfused patients. After adjustment 
Table V. Independent predictors of six-month mortality
Variable Hr (95% CI) p
Age (per 1-year increase) 1.03 (1.01-1.06) 0.002
Killip class >I 2.12 (1.41-3.19) <0.0001
Left ventricular systolic dysfunction* 2.30 (1.34-3.97) 0.003
GFR (per 10-ml/min/1.73 m2 decrement) 1.11 (1.03-1.19) 0.007
Hemoglobin drop (per 1-g/dL increase) 1.16 (1.01-1.32) 0.030
Coronary revascularization 0.48 (0.29-0.78) 0.003
Blood transfusion 1.94 (1.06-3.55) 0.032
*Left ventricular ejection fraction <50% as estimated by echocardiography. GFR:	glomerular	filtration	rate.
Figure 4. Crude six-month mortality according to hemoglobin drop (g/dL), stratified by type of acute coronary syndrome: 
ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndromes (NSTE-
ACS). At the top of each column, the rates of six-month mortality (% of patients) are noted. Data labels at the bottom of 
the columns refer to the number of patients in each group of hemoglobin drop.
*p=0.04 for trend; †p=0.001 for trend.
Hemoglobin drop, g/dl
392
rev Port Cardiol
Vol. 28 abril 09 / april 09  
dilution” by nitroglycerin and normalization of 
the previous stress-induced hemoconcentration. 
Providing further evidence for the latter 
hypothesis, we also found that patients with 
higher hemoglobin drop had increased levels 
on admission of common markers of stress such 
as white blood cell count, platelet count, and 
blood glucose. We observed that patients who 
eventually had greater hemoglobin drop during 
hospitalization had higher blood pressure on 
admission, which may be due to increased 
neurohumoral activation on presentation 
and later normalization of stress-induced 
hemoconcentration. Chronic use of ACE 
inhibitors may contribute to anemia by inhibiting 
erythropoiesis, although their role in the acute 
setting is not clear(21). Diagnostic phlebotomy may 
also contribute to blood loss and cause anemia 
in hospitalized patients(22). However, the use of 
small volume blood containers and reduction 
of the frequency of sampling after discharge 
from the ICCU suggests that phlebotomy has a 
minor role in hemoglobin decline in our patient 
population(20,23). 
Major contributors to hemoglobin drop in 
our study included the use of therapeutic agents 
such as thrombolytic therapy and glycoprotein 
IIb/IIIa inhibitors. We also observed that older 
age, lower body weight, and reduced GFR 
were associated with increased hemoglobin 
decline. These three factors, among others, have 
previously been associated with excess dosing 
of unfractionated heparin, low molecular weight 
heparin, and glycoprotein IIb/IIIa inhibitors in 
an analysis from the CRUSADE registry(24). In 
that report, dosing errors predicted an increased 
risk of major bleeding and were associated with 
increased mortality(24). Although we do not have 
data regarding the dose of antithrombotic agents 
and glycoprotein IIb/IIIa inhibitors used in our 
population,	 these	 findings	 may	 suggest	 that	
dosing errors might have contributed to bleeding 
and hemoglobin drop in our patients.
Although 25% of patients had a decline in 
hemoglobin of at least 2.4 g/dL during hospital 
course, major and minor bleeding (TIMI criteria) 
occurred in only 2.1% and 7.4% of our population 
respectively. Furthermore, among 106 patients 
in our study who had a hemoglobin drop of 3 
to 4 g/dL, only 43 (40.6%) had an observed 
blood loss. This implies that clinically occult 
bleeding, such as unrecognized gastrointestinal 
on prognosis among patients who have had an 
ACS(3-5,17,18).
Current management of ACS patients with 
anticoagulants, antiplatelet agents, thrombolytic 
treatment (in the case of ST-elevation MI), and 
percutaneous or surgical revascularization has 
improved the rate of ischemic events at the cost 
of a higher risk of bleeding complications(19). 
Predictors of an increased decline in hemoglobin 
concentration in our study included older age, 
reduced GFR, lower weight, higher admission 
hemoglobin, and the use of intravenous inotropic 
agents, thrombolytic therapy, glycoprotein IIb/
IIIa inhibitors, nitrates, and percutaneous cor - 
o nary revascularization procedures. These 
risk factors were similar to previously iden-
tified	 determinants	 of	 major	 bleeding	 in	 a	
large registry of ACS(5). Previous data are 
heterogeneous regarding female gender as a risk 
factor for bleeding(3,5,7,18). In the present study, 
female gender was not associated with increased 
hemoglobin drop. In our patient population, 
women were more often admitted with non-ST-
elevation ACS (55.0% in women vs. 47.3% in 
men; p=0.019), had lower baseline hemoglobin 
concentration (12.6±1.5 g/dL vs. 14.4±1.6 g/
dL; p<0.001), and less frequently underwent 
thrombolytic treatment (17.9% vs. 32.0%; 
p<0.001), percutaneous coronary intervention 
(18.5% vs. 35.8%; p<0.001), and glycoprotein 
IIb/IIIa inhibitors (2.7% vs. 5.5%; p=0.047), 
thus partly explaining the lower hemoglobin 
drop among women.
Hemoglobin drop and development of anemia 
among patients hospitalized with ACS may result 
from different mechanisms in addition to blood 
loss. In our study, patients with increased levels 
of hemoglobin decline more often developed 
signs of heart failure and congestion, and 
were more frequently treated with nitrates and 
ACE inhibitors. Furthermore, although these 
patients had higher hemoglobin concentrations 
on admission, they developed lower nadir 
hemoglobin	 levels.	 These	 findings	 suggest	 that	
hemodilution might be involved in hemoglobin 
drop during hospital course. Previsdomini et 
al.(20) described a mean hemoglobin decrease of 
1.29±0.79	g/dL	during	 the	first	12	 to	24	hours	
(remaining constant during the rest of hospital 
stay) in 103 nonbleeding patients with ACS in 
an intensive care unit. The authors hypothesized 
that this decrease is due to “internal hemo-
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transfusion was independently associated with 
a 1.9-fold higher risk of 6-month mortality, 
after adjustment for baseline characteristics, 
hemoglobin drop, and interventions. This 
finding	 is	 consistent	 with	 previous	 reports	 on	
adverse effects of transfusion in patients with 
ACS(7-9).	 However,	 transfusion	 may	 reflect	
a more critical condition and many factors 
involved in the clinical decision to transfuse 
cannot be adjusted for in a statistical model(26). 
Although the mechanisms linking adverse 
outcomes with red-cell transfusion remain 
unclear, several factors may contribute. It was 
shown recently that transfusion of older units 
of red cells (more than 14 days of storage) is 
associated with worse outcomes after cardiac 
surgery(27).	This	finding	provides	more	evidence	
in support of the concept that progressive 
functional and structural changes undergone 
by red cells during storage may underlie the 
increased risk associated with blood transfusion 
in some patients. Stored red cells are depleted 
in intracellular 2,3-diphosphoglycerate, which 
shifts the oxyhemoglobin dissociation curve 
to the left and reduces oxygen delivery to the 
tissues(28). Stored red cells are also depleted 
in nitric oxide and adenosine triphosphate, 
and may act as a nitric oxide sink, resulting in 
vasoconstriction and reduced oxygen carriage 
by the blood(3,29). Storage of red cells also results 
in decreased deformability, increased adhesive-
ness and aggregability, and accumulation of 
proinflammatory	 bioactive	 substances,	 thereby	
triggering or worsening ischemic events(27,30). 
Potentially deleterious consequences of a 
transfusion on cardiac performance may also 
include	increased	blood	viscosity,	fluid	overload,	
and immune suppression(26).
Wu and colleagues(31) reported that in 
elderly patients with MI, blood transfusion was 
associated with lower short-term mortality if 
baseline hematocrit was ≤30.0%. However, in a 
randomized trial of critically ill patients, there 
was	 a	 nonsignificant	 difference	 in	 mortality	
between patients administered transfusion at 
hemoglobin of 7 g/dL versus those administered 
transfusion at a hemoglobin of 10 g/dL(32). 
Recently, Alexander et al.(33) analyzed the 
association between transfusion and in-hospital 
mortality as a function of nadir hematocrit in 
non-ST-segment elevation ACS patients in the 
CRUSADE	 registry.	 No	 significant	 adverse	
oozing,	might	 have	 contributed	 to	 a	 significant	
hemoglobin drop(19,25).  
Our study suggests that hemoglobin decline 
is common during hospitalization for ACS and 
is associated with worse prognosis, in terms 
of death and MI, after adjustment for baseline 
characteristics and interventions, including 
blood transfusion. This is consistent with recent 
observational data suggesting that bleeding is 
associated with a higher risk of ischemic events 
and death(3-5,17,18). Aronson and colleagues(15) 
have previously shown that nadir and discharge 
hemoglobin levels have a strong impact on 
death and occurrence of heart failure in the 
short and long term among survivors of MI. Our 
data on consecutive patients with ACS are in 
agreement	with	 the	findings	by	Aronson	 et	 al.,	
and shed further light on the prognostic impact 
of hemoglobin drop during hospitalization. The 
16% adjusted increase in the risk of death for 
each 1-g/dL increment in hemoglobin drop 
in our study compares to the 21% adjusted 
increase in the risk of post-discharge death for 
each 1-g/dL increment in hemoglobin drop in 
the aforementioned report(15).
Several possible mechanisms may underlie 
the association of hemoglobin decline 
and bleeding with adverse outcomes. The 
development of anemia with inherent risk of 
inadequate tissue oxygen delivery is probably 
one of the mechanisms involved in the 
association of hemoglobin drop with increased 
mortality and re-infarction(19). Patients with 
increased levels of hemoglobin drop had lower 
levels of nadir hemoglobin concentration, and 
nadir hemoglobin was strongly associated with 
increased mortality in our study and previous 
reports(15).	We	found	a	non-significant	 tendency	
for a J-shaped relationship between nadir 
hemoglobin	and	adjusted	mortality.	This	finding	
was not reported in previous studies and is most 
likely due to chance. 
Bleeding often leads to the discontinuation 
of antithrombotic therapy, which might result in 
ischemia, MI, stent thrombosis, hemodynamic 
decompensation, and arrhythmias(17). It may also 
result in hemodynamic compromise, greater 
neurohormonal activation, exaggeration of 
inflammatory	 response,	 and	 platelet	 activation,	
which portends an increased risk of recurrent 
ischemic events(3,15,19). Furthermore, transfusion 
may also add to the risk. In our study, blood 
394
rev Port Cardiol
Vol. 28 abril 09 / april 09  
a function of nadir hemoglobin. Fifth, we were 
unable to explore possible relationships between 
antithrombotic and antiplatelet therapy (dosing, 
timing, and cessation), hemoglobin drop, and 
observed outcomes. In addition, no prospective 
data were collected regarding the use of 
gastrointestinal protective agents (histamine-2 
antagonists, proton pump inhibitors), which 
should have been considered in the Cox model. 
Finally, data regarding minimal bleeding without 
significant	 hemoglobin	 drop	 (<3	 g/dL)	 were	
not collected for the entire patient population. 
Therefore,	we	were	unable	to	perform	a	stratified	
analysis of patients who presented clinical 
bleeding events versus those who did not bleed, 
and to correlate hemoglobin drop with clinical 
bleeding events. Future observational studies 
designed to address these issues are required 
to better explore the mechanisms that underlie 
the relationship between hemoglobin drop and 
adverse outcomes.
CoNCluSIoNS
Our data show that a decrease in hemoglobin 
is frequent during hospitalization for ACS and is 
independently associated with adverse events in 
follow-up. Predictors of increased hemoglobin 
decline	were	 identified	 and	 include	 older	 age,	
renal dysfunction, lower weight, higher baseline 
hemoglobin, and use of thrombolytic therapy, 
glycoprotein IIb/IIIa inhibitors, nitrates, 
intravenous inotropic agents, and percutaneous 
coronary intervention. The development of 
anemia and blood transfusion may partly 
contribute to the worse outcomes observed with 
higher levels of hemoglobin drop.
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effects with transfusion were found in those 
with nadir hematocrit of <30%, and there was 
a	strong	trend	to	benefit	when	nadir	hematocrit	
was ≤24%. The small sample size did not allow 
us to perform a similar analysis in our population. 
A randomized trial of transfusion strategies is 
required to clarify the indications for its use in 
this setting. 
Our study provides further support for the 
potential importance of reducing bleeding risk 
in the treatment of ACS patients. This should 
involve the careful use of pharmacological 
therapy and reperfusion/revascularization 
strategies. Particular attention should be paid in 
elderly patients and in renal dysfunction. Possible 
options include correct dosing of unfractionated 
heparin, low molecular weight heparin, and 
glycoprotein IIb/IIIa inhibitors according to 
weight and renal function, consideration of 
fondaparinux as well as bivalirudin, use of 
gastroprotective agents, and careful use of dual 
antiplatelet therapy. The choice of a radial 
vascular approach over the femoral route (which 
was used in >90% of patients in our study) may 
also help to reduce bleeding risk(1,2).
lIMItatIoNS
There are several limitations to be 
considered when our study is interpreted. First, 
this was a retrospective observational and non-
randomized study conducted at a single hospital, 
and	 as	 such,	 both	 identified	 and	 unidentified	
confounders	may	have	influenced	the	outcomes	
and causality could not be determined. Second, 
patients	 (n=8)	 transferred	 in	 the	 first	 24	hours	
to other centers for urgent cardiac surgery or 
coronary revascularization were excluded from 
analysis. Third, hemoglobin determinations 
after discharge from the ICCU were obtained 
according to the discretion of the attending 
cardiologist, except after percutaneous coronary 
intervention; transfusions were not accounted 
for in the calculation of nadir hemoglobin; 
and data on bleeding events and hemoglobin 
decline occurring after CABG surgery were 
not evaluated. Therefore, some patients may 
have	 been	 misclassified	 regarding	 hemoglobin	
decline during hospital course. Fourth, the 
small sample size did not allow us to analyze the 
association between transfusion and outcome as 
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